Contributing metabolites included fumarate, succinate, citrate, and 2-hydroxyglutarate, while major proteomic contributors included MPC1, PDHB, DLAT, DLST, IDH3, SDHB, and FH.<h4>Conclusions</h4>AI-derived MRI tumor-volume changes after CRT correspond to specific serum proteomic and metabolomic alterations, highlighting metabolic pathways linked to contrast-enhancing tissue dynamics in GBM. The gene discussed is PDHB; the disease is glioblastoma.